Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
VICOPROFEN is a fixed-dose oral tablet combining hydrocodone bitartrate (opioid analgesic) and ibuprofen (NSAID) approved in 1997 for moderate to moderately severe pain. The combination leverages synergistic mechanisms: hydrocodone provides opioid analgesia while ibuprofen adds peripheral anti-inflammatory and analgesic effects, enabling lower opioid doses. This dual mechanism targets patients requiring moderate pain relief with reduced opioid exposure.
As an aging product approaching LOE with moderate competitive pressure (30/100), the brand team is likely focused on defensive strategies and cost management rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings reflect this product's LOE-approaching status at AbbVie, indicating limited hiring and career growth on the brand itself. Professionals assigned to VICOPROFEN should prioritize mentorship, cross-functional visibility, and readiness for portfolio transitions or internal mobility.
Worked on VICOPROFEN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.